Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytoskeletal Linker Proteins - Plakins

Cytoskeletal Linker Proteins - Plakins

Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...

Restarting Stalled Replication Forks

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...

Covalently Linked Protein Regulators

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Activation of parkin by a molecular glue.

Nature communications·2024

Same author

Naturally occurring hyperactive variants of human parkin.

Communications biology·2024

Same author

Enhanced binding of guanylated poly(A) RNA by the LaM domain of LARP1.

RNA biology·2024

Same author

Structural insights into regulation of CNNM-TRPM7 divalent cation uptake by the small GTPase ARL15.

eLife·2023

Same author

New insights into the structure and function of CNNM proteins.

The FEBS journal·2023

Same author

Structural basis of 3'-end poly(A) RNA recognition by LARP1.

Nucleic acids research·2022

Search research articles

Related Experiment Video

Updated: Jun 4, 2025

Spatiotemporally Controlled Nuclear Translocation of Guests in Living Cells Using Caged Molecular Glues as Photoactivatable Tags

Spatiotemporally Controlled Nuclear Translocation of Guests in Living Cells Using Caged Molecular Glues as Photoactivatable Tags

Published on: January 17, 2019

A molecular glue for PRKN/parkin.

Véronique Sauvé¹, Kalle Gehring¹

¹Department of Biochemistry and Centre de Recherche en Biologie Structurale, McGill University, Montreal, QC, Canada.

|December 19, 2024

Summary

A small molecule drug activates Parkinson

Area of Science:

Neuroscience and Neurodegenerative Diseases
Cellular Biology and Autophagy

Background:

Parkinson disease (PD) involves the loss of dopaminergic neurons, often linked to mitochondrial dysfunction.
Mutations in PRKN (parkin) and PINK1 are associated with early-onset PD and are crucial for clearing damaged mitochondria through mitophagy.

Purpose of the Study:

To investigate a small molecule's potential to restore mitophagy in Parkinson disease models.
To explore therapeutic strategies for PD by targeting PRKN mutations.

Main Methods:

Utilized cellular assays to examine the effect of a small molecule on PRKN mutants.
Assessed the restoration of mitophagy in response to the small molecule treatment.

Main Results:

A novel small molecule was found to activate PRKN mutants that resist phosphorylation.

Keywords:

Activator PARK2 mitochondria neurodegeneration parkinson disease ubiquitin

More Related Videos

PAR-CliP - A Method to Identify Transcriptome-wide the Binding Sites of RNA Binding Proteins

PAR-CliP - A Method to Identify Transcriptome-wide the Binding Sites of RNA Binding Proteins

Published on: July 2, 2010

OaAEP1-Mediated Enzymatic Synthesis and Immobilization of Polymerized Protein for Single-Molecule Force Spectroscopy

OaAEP1-Mediated Enzymatic Synthesis and Immobilization of Polymerized Protein for Single-Molecule Force Spectroscopy

Published on: February 5, 2020

Related Experiment Videos

Last Updated: Jun 4, 2025

Spatiotemporally Controlled Nuclear Translocation of Guests in Living Cells Using Caged Molecular Glues as Photoactivatable Tags

Spatiotemporally Controlled Nuclear Translocation of Guests in Living Cells Using Caged Molecular Glues as Photoactivatable Tags

Published on: January 17, 2019

PAR-CliP - A Method to Identify Transcriptome-wide the Binding Sites of RNA Binding Proteins

PAR-CliP - A Method to Identify Transcriptome-wide the Binding Sites of RNA Binding Proteins

Published on: July 2, 2010

OaAEP1-Mediated Enzymatic Synthesis and Immobilization of Polymerized Protein for Single-Molecule Force Spectroscopy

OaAEP1-Mediated Enzymatic Synthesis and Immobilization of Polymerized Protein for Single-Molecule Force Spectroscopy

Published on: February 5, 2020

This activation successfully restored mitophagy in cellular assays, indicating improved clearance of damaged mitochondria.

Conclusions:

The study identifies a promising therapeutic approach for specific forms of Parkinson disease.
Findings suggest that small molecules can be designed to overcome PRKN-related defects, offering hope for novel PD drug development.